Early mortality and overall survival in oncology phase I trial participants: can we improve patient selection?
<p>Abstract</p> <p>Background</p> <p>Patient selection for phase I trials (PIT) in oncology is challenging. A typical inclusion criterion for PIT is 'life expectancy > 3 months', however the 90 day mortality (90DM) and overall survival (OS) of patients with...
Main Authors: | Bedard Philippe, Chen Eric X, Wang Lisa, Chan Kelvin K, Florescu Ana, Chau Nicole G, Oza Amit M, Siu Lillian L |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2011-10-01
|
Series: | BMC Cancer |
Online Access: | http://www.biomedcentral.com/1471-2407/11/426 |
Similar Items
-
Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology
by: Sherrill B, et al.
Published: (2012-10-01) -
Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials
by: Wu-Hao Lin, et al.
Published: (2021-04-01) -
Canada: Can we survive? [audiorecording]
by: Cairns, Alan
Published: (2009) -
Measuring Quality of Life in Ovarian Cancer Clinical Trials—Can We Improve Objectivity and Cross Trial Comparisons?
by: Gita Bhat, et al.
Published: (2020-11-01) -
What can we learn from cancer of unknown primary in canine oncology?
by: Aline Khazzaka, et al.
Published: (2020-07-01)